PEER-REVIEWED PAPERS
Freeman TC, Ivens A, Baillie JK, Beraldi D, Barnett MW, Dorward D, Downing A, Fairbairn L, Kapetanovic R, Raza S, Tomoiu A, Alberio R, Wu C, Su AI, Summers KM, Tuggle CK, Archibald AL, Hume DA. “A gene expression atlas of the domestic pig.” BMC Biol, Vol. 10, No. 90 (November 15), 2012.
Rameix-Welti MA, Tomoiu A, Dos Santos Afonso E, van der Werf S, Naffakh N. “Avian Influenza A Virus Polymerase Association with Nucleoprotein, but Not Polymerase Assembly, Is Impaired in Human Cells during the Course of Infection.” J Virol, Vol. 83, No. 3 (February), 2009: pp. 1320-1331.
Naffakh N, Tomoiu A, Rameix-Welti MA, van der Werf S. “Host restriction of avian influenza viruses at the level of the ribonucleoproteins.” Annu Rev Microbiol, Vol. 62, 2008: pp. 403-424.
Tomoiu A, Larbi A, Dupuis S, Fülöp T. “Do membrane rafts contribute to human immunosenescence?” Ann N Y Acad Sci, Vol. 1100 (April), 2007: pp. 98-110.
Gravel A, Tomoiu A, Flamand L. “La phase très précoce de l’infection par le sixième herpèsvirus humain : rôle des protéines IE1 et IE2.” Virologie, Vol. 11, No. 3 (May-June), 2007: pp. 181-193.
Tomoiu A, Flamand L. “Epitope Mapping of a Monoclonal Antibody Specific for Human Herpesvirus 6 Variant A Immediate-Early 2 Protein.” J Clin Virol, Vol. 38, No. 4 (April), 2007: pp. 286-291.
Tomoiu A, Gravel A, Tanguay RM, Flamand L. “Functional Interaction between Human Herpesvirus 6 Immediate-Early 2 Protein and Ubiquitin-Conjugating Enzyme 9 in the Absence of Sumoylation.” J Virol, Vol. 80, No. 20 (October), 2006: pp. 10218-10228.
Tomoiu A, Gravel A, Flamand L. “Mapping of Human Herpesvirus 6 Immediate-Early 2 Protein Transactivation Domains.” Virology, Vol. 354, No. 1 (October 10), 2006: pp. 91-102.
Tomoiu A, Flamand L. “Biological and Clinical Advances in Human Herpesvirus-6 and -7 Research.” Future Virol, Vol. 1, No. 5 (September), 2006: pp. 623-635.
Gravel A, Tomoiu A, Cloutier N, Gosselin J, Flamand L. “Characterization of the Immediate-Early 2 Protein of Human Herpesvirus 6, a Promiscuous Transcriptional Activator.” Virology, Vol. 308, No. 2 (April 10), 2003: pp. 340-353.
Bélanger C, Gravel A, Tomoiu A, Janelle ME, Gosselin J, Tremblay MJ, Flamand L. “Human Herpesvirus 8 Viral FLICE-inhibitory Protein Inhibits Fas-mediated Apoptosis Through Binding and Prevention of Procaspase-8 Maturation.” J Hum Virol, Vol. 4, No. 2 (March/April), 2001: pp. 62-73.
Gosselin J, Tomoiu A, Gallo RC, Flamand L. “Interleukin-15 as an Activator of Natural Killer Cell-Mediated Antiviral Response.” Blood, Vol. 94, No. 12 (December 15), 1999: pp. 4210-4219.
SELECTED CONFERENCE PAPERS
Tomoiu A, Baillie JK, Hume DA. “The role of host genetics in susceptibility to influenza.” Mechanisms of Severe Acute Influenza Consortium (MOSAIC) 5th Investigator Meeting, London, September 18, 2012.
Tomoiu A, Baillie JK, Hume DA. “Alveolar macrophage involvement in the pathogenesis of influenza A virus.” European Macrophage and Dendritic Cell Society 2012 Meeting, Debrecen, September 1-3, 2012.
Tomoiu A, Rameix-Welti MA, Jacob Y, Vidalain PO, Flynn D, Tangy F, van der Werf S, Naffakh N. “Identification of cellular factors interacting with the polymerase complex of influenza A viruses.” 162nd Meeting of the Society for General Microbiology, Edinburgh, March 31-April 3 2008.
Tomoiu A, Rameix-Welti MA, Jacob Y, Vidalain PO, van der Werf S, Naffakh N. “Identification of cellular factors interacting with the polymerase complex of influenza A viruses.” 2nd FluInnate Meeting, Siena, January 18-19 2008.
Tomoiu A, Gravel A, Flamand L. “Functional Interactions between Human Herpesvirus-6 Immediate-Early 2 Protein and Ubiquitin-Conjugating Enzyme 9 in the Absence of Sumoylation.” 5th International Conference on HHV-6 & 7, Barcelona, April 30-May 3 2006.
Tomoiu A, Gravel A, Flamand L. “Mapping of Transactivation Domains of Human Herpesvirus-6 Immediate-Early 2 Protein.” 5th International Conference on HHV-6 & 7, Barcelona, April 30-May 3 2006.
Tomoiu A, Gravel A, Janelle ME, Pelletier G, Flamand L. “Functional Characterization of Human Herpesvirus-6 Immediate-Early 2 Protein.” 23rd Annual Meeting of the American Society for Virology, Montréal, July 10-14 2004.
Tomoiu A, Gravel A, Janelle ME, Gosselin J, Flamand L. “Altération des domaines oncogéniques associés à PML lors de l’infection par l’herpèsvirus humain 6.” 43e Réunion annuelle du Club de recherches cliniques du Québec, Mont Saint-Anne, Sept. 20-22 2001.
Tomoiu A, Gravel A, Janelle ME, Gosselin J, Flamand L. “Involvement of Protein IE2 in Establishment of Infection by Human Herpesvirus-6.” 11th International Congress of Immunology, Stockholm, July 22-27 2001.
Tomoiu A, Gosselin J, Flamand L. “SUMO-1 et hUbc9 augmentent la capacité de transactivation de la protéine IE2 de l’herpèsvirus humain 6.” 42e Réunion annuelle du Club de recherches cliniques du Québec, Bromont, Sept. 28-30 2000.
Tomoiu A, Létourneau V, Gosselin J, Flamand L. “Interleukine-15 et infections virales.” 41e Réunion annuelle du Club de recherches cliniques du Québec, Montebello, Oct 14-17 1999.
Tomoiu A, Gosselin J, Flamand L. “Interaction Between U86 of Human Herpesvirus 6 and the Ubiquitin-Conjugating Enzyme 9 (hUBC9).” 1999 International Meeting of the Institute of Human Virology, Baltimore, Aug. 28-Sept. 2 1999.
Tomoiu A, Blanchard L, Gosselin J, Flamand L. “Characterization of ORFs 86 and 89, two Transactivating Genes of Human Herpesvirus-6.” 12th Spring Meeting of the Canadian Society for Immunology, Ste-Adèle, March 13-16 1998.
OTHER PUBLICATIONS
Tomoiu A, “Caractérisation fonctionnelle de la protéine précoce-immédiate 2 de l’herpèsvirus humain 6.”, PhD Thesis, Faculté de médecine, Université Laval, Québec, 2007. http://archimede.bibl.ulaval.ca/archimede/fichiers/24149/24149.html
Andru Tomoiu 